Latest News

Treatment with satricabtagene autoleucel met the primary end point of progression-free survival in the phase 2 CT041-ST-01 trial.
Satri-cel Improves PFS in CLDN18.2+ Advanced Gastric/GEJ Cancers

January 3rd 2025

Treatment with satricabtagene autoleucel met the primary end point of progression-free survival in the phase 2 CT041-ST-01 trial.

Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
FDA Approves Tislelizumab/Chemo in Gastric/GEJ Adenocarcinoma

December 27th 2024

X-ray Brachytherapy Sustains Organ Preservation in Early Rectal Cancer
X-ray Brachytherapy Sustains Organ Preservation in Early Rectal Cancer

December 22nd 2024

Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer

December 16th 2024

Tislelizumab/Chemo Approved by European Commission For ESCC/GEJ
Tislelizumab/Chemo Approved by European Commission For ESCC/GEJ

November 27th 2024